Early DHA Supplementation in Very Low Birth Weight Infants
NCT ID: NCT03192839
Last Updated: 2019-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2017-07-01
2018-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PUFA Supplementation in Premature Infants
NCT01955044
Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
NCT06207071
A Randomized Clinical Trial on Supplementation of DHA and AA to Preterm Infants
NCT00226187
Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants
NCT01908907
A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders
NCT02336243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose PUFA
Low dose PUFA
Low dose PUFA
High dose PUFA
High dose PUFA
High dose PUFA
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose PUFA
Low dose PUFA
High dose PUFA
High dose PUFA
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Consent signed within 72 hours of life
Exclusion Criteria
* Infants with known congenital GI anomaly
* Infants who are deemed to be inappropriate for enrollment per attending neonatologist
3 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
North Shore Research Institue
UNKNOWN
Mead Johnson Nutrition
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Timothy Cooper, M.D
Role: STUDY_DIRECTOR
Mead Johnson Nutrition
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
North Shore University Health System
Evanston, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Frost BL, Patel AL, Robinson DT, Berseth CL, Cooper T, Caplan M. Randomized Controlled Trial of Early Docosahexaenoic Acid and Arachidonic Acid Enteral Supplementation in Very Low Birth Weight Infants. J Pediatr. 2021 May;232:23-30.e1. doi: 10.1016/j.jpeds.2020.12.037. Epub 2021 Feb 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6039
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.